A prime exchange-traded fund supplier is betting on the long-term reputation of GLP-1 weight reduction medication.
Roundhill Investments’ GLP-1 & Weight Loss ETF (OZEM), which started buying and selling final week, pairs leaders Eli Lilly and Novo Nordisk with gamers creating new remedies for weight reduction and diabetes. CEO Dave Mazza mentioned his agency is capitalizing on explosive progress potential within the business.
“The power to have lively administration to chubby corporations which might be really in market producing the medication after which go down the road to establish these which might be particularly phases is highly effective,” Mazza instructed CNBC’s “ETF Edge” final Monday.
Eli Lilly and Novo Nordisk every maintain a roughly 20% weighting within the ETF, per Roundhill’s web site as of Friday. The three subsequent largest positions are Zealand Pharma, Amgen and Chugai Pharmaceutical, every of which have a weighting underneath 5%.
Previously yr, Eli Lilly is up 90%, whereas Novo Nordisk has gained 68%, as of Friday’s market shut. Mazza waived issues that buyers have missed out on the rally, noting the load loss drug business remains to be in its “early days.”
“{The marketplace} has loads of room for progress with different corporations coming in, whether or not they’re with extra highly effective medication or with issues that truly you need not have an injectable.”
He additionally sees GLP-1 drugmakers following an analogous trajectory to AI-linked shares.
“It is a bit of bit like interested by Nvidia with AI. They simply have a head begin,” Mazza mentioned. “[Eli Lilly and Novo Nordisk] pivoted to give attention to diabetes and weight reduction medication a number of years in the past, had been in a position to get in market and produce outcomes which might be exceptional.”
After final Tuesday’s launch, shares of Roundhill’s GLP-1 & Weight Loss ETF ended the week down by nearly 2%.